KR20040022134A - Method for anticancer treatment using human mesenhymal stem cell and adenovirus producing p53 - Google Patents

Method for anticancer treatment using human mesenhymal stem cell and adenovirus producing p53 Download PDF

Info

Publication number
KR20040022134A
KR20040022134A KR1020020054787A KR20020054787A KR20040022134A KR 20040022134 A KR20040022134 A KR 20040022134A KR 1020020054787 A KR1020020054787 A KR 1020020054787A KR 20020054787 A KR20020054787 A KR 20020054787A KR 20040022134 A KR20040022134 A KR 20040022134A
Authority
KR
South Korea
Prior art keywords
mesenchymal stem
stem cells
stem cell
cancer
cells
Prior art date
Application number
KR1020020054787A
Other languages
Korean (ko)
Inventor
송준석
윤원석
Original Assignee
송준석
윤원석
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 송준석, 윤원석 filed Critical 송준석
Priority to KR1020020054787A priority Critical patent/KR20040022134A/en
Publication of KR20040022134A publication Critical patent/KR20040022134A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

PURPOSE: A method of treating cancer using a human mesenchymal stem cell in which an amount of p53 expression is increased by the infection of a p53 adenovirus vector into the human mesenchymal stem cell is provided. The human mesenchymal stem cell for excessive secretion of p53 causes excessive secretion of the p53 to kill cancer cells and inhibits the growth without antigen-antibody reaction and thus is expected to be directly administered to a cancer patient. CONSTITUTION: A human mesenchymal stem cell is genetically modified using a p53 adenovirus vector to cause the excessive secretion of p53 as cancer inhibiting protein and it is used for anti-cancer treatment. For instance, the human mesenchymal stem cell is infected with a p53 adenovirus vector to cause the excessive secretion of p53 as a cancer suppressor gene.

Description

인간 간엽줄기 세포와 p53 분비 아데노바이러스를 이용한 항암치료방법{Method for anticancer treatment using human mesenhymal stem cell and adenovirus producing p53}Method for anticancer treatment using human mesenhymal stem cell and adenovirus producing p53}

줄기 세포를 이용한 의료 연구는 기존의 의학적 한계를 뛰어넘는 새로운 형태의 의학으로 21 세기 의학기술에서 중요한 위치를 차지하리라 본다. 줄기 세포란 분화(differentiation)되지 않은 세포로써, 증식(proliferation)되고 분화되어 어떤 특정 조직(tissue)이나 기관(organ)을 형성할 수 있는 능력을 가진 세포를 말한다. 줄기 세포를 크게 구별하면 성인 골수(adult bone marrow)에서 얻는 간엽 줄기 세포 (mesenchymal stem cell; MSC) 와 같은 성인 줄기 세포 (adult stem cell)와배자 (embryo) 와 태아 (fetus) 에서 얻는 배자, 태아 줄기 세포 (embryonic ＆ fetal stem cell) 로 대별된다. 현재까지의 연구 결과에 따르면 성인 줄기 세포에서 연골 (cartilage), 지방 (fat), 근육 (muscle), 조혈(hematopoietic) 그리고 신경 세포인 성상 세포 (astrocyte) 를 얻을 수 있다.Medical research using stem cells is a new type of medicine that goes beyond existing medical limitations and will hold an important place in 21st century medical technology. Stem cells are cells that are not differentiated and that have the ability to proliferate and differentiate to form certain tissues or organs. The main distinction between stem cells is adult stem cells, such as mesenchymal stem cells (MSCs) from adult bone marrow, embryos and embryos from embryos and fetuses. Stem cell (embryonic & fetal stem cell). To date, research has shown that adult stem cells can produce cartilage, fat, muscle, hematopoietic and neuronal astrocytes (astrocytes).

유전자 치료 (gene therapy) 는 유전병과 암 등 각종 유전자 이상으로 유발되는 질병 치료를 위해 치료 유전자를 체내에 주입하는 방법으로 각종 치료 유전자에 의해 각종 질환의 치료 효과를 기대 할 수 있다. 유전자 치료의 가장 중요한 요건은 목적 유전자의 목표 세포에의 성공적 전달에 있다.이를 위해 리포좀 (liposome) 등의 운반체를 사용하여 유전자를 주입하거나, 아데노바이러스나 레트로 바이러스 등에 유전자를 실어 세포에 전달하게 되는데 이 두 방법 모두 세포에의 전달 효율이 극히 떨어지며 환자에게 불필요한 면역 반응을 유도해 생명을 잃기도 한다. 따라서 암세포 등 목적 세포에 특이적으로 작용하면서 동시에 그 발현 효율이 높은 새로운 유전자 전달 체계가 필요하다.Gene therapy is a method of injecting therapeutic genes into the body for the treatment of diseases caused by various genetic abnormalities such as genetic diseases and cancer, and can be expected to treat various diseases by various therapeutic genes. The most important requirement for gene therapy is the successful delivery of the target gene to the target cell, which involves injecting the gene using a carrier such as a liposome or loading the gene into an adenovirus or retrovirus. Both of these methods are extremely inefficient in cell delivery and can lead to unnecessary immune responses in patients, resulting in loss of life. Therefore, there is a need for a new gene delivery system that specifically acts on target cells such as cancer cells and has high expression efficiency.

p53 유전자는 암억제 유전자 (tumor suppressor gene) 로 대략 50~60 % 암환자의 p53 유전자가 변이 또는 결손되어 그 활성이 나타나지 않는다. 구체적으로 p53 단백질은 세포 내 DNA 손상 시 세포주기 G1 기에 멈추게 하여 DNA 손상 복구 과정을 통해 암세포 생성을 막는다. 또한 이미 성장한 암세포에는 세포 아폽토시스 (apoptosis)를 유발시켜 암세포를 사멸케 한다. 따라서 p53 유전자를 p53 변이가 있는 암세포에서 발현시키면 암세포의 사멸을 유도 할 수 있다.The p53 gene is a tumor suppressor gene, and its activity is not shown due to mutation or deletion of the p53 gene in approximately 50 to 60% of cancer patients. Specifically, p53 protein stops at the cell cycle G1 phase when intracellular DNA damage prevents the formation of cancer cells through DNA damage repair process. In addition, cancer cells that have already grown cause cellular apoptosis (apoptosis) to kill the cancer cells. Therefore, expression of p53 gene in cancer cells with p53 mutation can induce the death of cancer cells.

현재 까지 연구 결과에 따르면 간엽 줄기 세포는 자가 면역 반응을 일으키지않는 것으로 알려져 있다. 즉, 간엽 줄기 세포는 주조직 적합성 복합체(MHC) 를 갖음에도 불구하고, 면역학적으로 중성인 성질을 갖으므로 다른 사람에게서 이식받은 간엽 줄기 세포는 면역 거부 반응을 일으키지 않는다.To date, research has shown that mesenchymal stem cells do not cause an autoimmune response. In other words, the mesenchymal stem cells have immunohistochemical properties despite having a major histocompatibility complex (MHC), so that the mesenchymal stem cells transplanted from others do not cause an immune rejection response.

따라서 조직 적합 항원이 서로 다른 환자에게도 간엽 줄기 세포의 이식이 가능하다. 또한 간엽 줄기 세포는 면역체계에서 회피되는 세포이다. 즉, 동종이형 T 림파구와 간엽 줄기 세포를 공배양시 T 세포에 의한 면역 반응이 일어나지 않음을 확인하였다.Thus, mesenchymal stem cells can be transplanted to patients with different tissue-compatible antigens. Mesenchymal stem cells are also cells that are evaded in the immune system. That is, the co-culture of allogeneic T lymphocytes and mesenchymal stem cells was confirmed that the immune response by T cells does not occur.

또한, Snyder 등에 의하면 신경 줄기 세포에 자살 유전자인 사이토신 다아미나제 (CD) 를 도입하고 이를 뇌종양 세포가 이식된 설치류에 주입하자 신경 줄기 세포가 뇌종양세포를 추적하여 대부분의 종양 세포를 괴사시켰음을 확인하였다. 본 발명에서는 간엽 줄기 세포도 신경 줄기세포와 같은 종양 특이적 부착능력이 있음을 확인하였다.In addition, according to Snyder et al., The introduction of the suicide gene cytosine daminase (CD) into neural stem cells and injecting them into rodents in which the brain tumor cells were transplanted neural stem cells followed the brain tumor cells to necrosis most tumor cells. Confirmed. In the present invention, it was confirmed that mesenchymal stem cells also have tumor-specific adhesion ability, such as neural stem cells.

본 발명의 목적은 인간 간엽 줄기 세포에 p53 분비 아데노바이러스 벡터를 감염시켜 p53 발현량이 증가된 유전적으로 변형된 간엽 줄기 세포를 이용하여 이를 항암 유전자 치료에 응용하는데 있다. 또한 간엽 줄기 세포에는 종양 추적능력이 있음으로 이렇게 유전적으로 변형된 간엽 줄기 세포는 종양을 추적해 종양 세포에 부착되어 과량의 p53을 분비함으로써 종양세포 만을 특이적으로 괴사 시킬 것으로 생각된다.It is an object of the present invention to apply p53 secreting adenovirus vectors to human mesenchymal stem cells and to apply them to anticancer gene therapy using genetically modified mesenchymal stem cells with increased p53 expression. In addition, since mesenchymal stem cells have tumor tracking ability, these genetically modified mesenchymal stem cells are likely to specifically attach tumor cells by attaching to tumor cells and secreting excess p53.

도 1은 간엽 줄기 세포의 아데노바이러스에 의한 유전자 전달 효율을 알아보기 위해 Ad5.CMV-LacZ 을 100 moi 감염시킨 후 X-gal 염색법을 시행한 결과이다.1 is a result of X-gal staining after 100 moi infection of Ad5.CMV-LacZ to determine the gene transfer efficiency of adenoviruses of mesenchymal stem cells.

도 2은 간엽 줄기 세포엔 종양 특이적 부착성이 있음을 확인한 그림이다.Figure 2 confirms that the mesenchymal stem cells have tumor-specific adhesion.

도 3는 p53 분비 아데노바이러스 감염 간엽 줄기 세포의 세포 상층액을 이용한 세포 사멸 효과를 나타낸 그림이다.Figure 3 is a diagram showing the cell death effect using the cell supernatant of p53 secretion adenovirus infected mesenchymal stem cells.

본 발명은 p53을 과량 발현하는 인간 간엽 줄기 세포의 제조방법 및 이를 이용한 항암 치료 방법을 제공한다.The present invention provides a method for producing human mesenchymal stem cells overexpressing p53 and an anticancer treatment method using the same.

이하, 본 발명을 실시예에 의해 더욱 상세히 설명한다. 하기 실시예들은 본 발명을 예시하는 것으로, 본 발명의 내용이 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples. The following examples are illustrative of the present invention, and the content of the present invention is not limited by the examples.

실시예 1 세포주 배양Example 1 Cell Line Culture

정상 사람 간엽 줄기 세포는 미국 바이오 휘테커 사 (Bio-whittaker, USA)에서 분양 받았으며, 간엽 줄기 세포 성장 배지 (MSCGM)을 사용하여 37℃ 5% CO₂의 조건에서 배양하였다. 인간 정상 피부 섬유 아세포 세포인 IMR90과 부유 (suspension) 위암 세포주인 SNU-16 세포주는 10% 소태아 혈청을 포함하는 배지 RPMI1640 에서 배양하여 사용하였다. 종양 세포주는 전립선암 세포주 Du-145, LN-CAP, 난소암 세포주 Ovca3 등을 이용하였다.Normal human mesenchymal stem cells were obtained from Bio-whittaker, USA and cultured at 37 ° C. 5% CO 2 using mesenchymal stem cell growth medium (MSCGM). Human normal dermal fibroblast cells, IMR90 and suspension gastric cancer cell line, SNU-16 cell line, were cultured and used in medium RPMI1640 containing 10% fetal bovine serum. Tumor cell lines used prostate cancer cell line Du-145, LN-CAP, ovarian cancer cell line Ovca3.

간엽 줄기 세포주를 제외한 모든 세포주는 한국 세포주 은행에서 구입하였다.All cell lines except mesenchymal stem cell lines were purchased from Korea Cell Line Bank.

실시예 2 p53 과량 분비하는 인간 간엽 줄기 세포의 제조Example 2 Preparation of p53 Oversecreting Human Mesenchymal Stem Cells

아데노바이러스 Ad5.CMV-LacZ, Ad5.CMV-hp53 바이러스는 미국 퀀탐사(Quantum-Appligene,USA) 에서 구입하였다. 간엽 줄기 세포의 아데노바이러스에 의한 유전자 전달 효율을 알아보기 위해 Ad5.CMV-LacZ을 10, 100 moi 감염시킨 후 X-gal 염색법을 시행하였다. 그 결과 moi 에 관계없이 거의 100% 세포가 감염됨을 확인한다 (도 1). p53을 과량 분비하는 간엽 줄기 세포의 제조를 위해 Ad5.CMV-hp53 바이러스를 10, 100 moi 씩 간엽 줄기 세포에 1시간 감염 후 새 배지로 바꿔주었다. 이때 100 moi Ad5.CMV-hp53 처리한 간엽 줄기 세포의 거의 대부분이 사멸함을 확인해서 과량의 p53 분비를 위한 간엽줄기 세포의 제조에는 10 moi 의 Ad5.CMV-hp53 사용이 유리함을 확인한다.Adenovirus Ad5.CMV-LacZ, Ad5.CMV-hp53 virus was purchased from Quantum-Appligene, USA. To examine the gene transfer efficiency of adenoviruses in mesenchymal stem cells, X-gal staining was performed after 10, 100 moi of Ad5.CMV-LacZ infection. As a result, it was confirmed that almost 100% of cells were infected regardless of moi (FIG. 1). To prepare mesenchymal stem cells that secrete p53, Ad5.CMV-hp53 virus was changed to fresh medium after 1 hour infection with mesenchymal stem cells at 10 and 100 moi. At this time, almost all of the mesenchymal stem cells treated with 100 moi Ad5.CMV-hp53 were killed, confirming the use of 10 moi of Ad5.CMV-hp53 for the preparation of mesenchymal stem cells for excessive p53 secretion.

실시예 3 간엽 줄기 세포의 종양 특이적 부착성 확인Example 3 Confirmation of Tumor Specific Adhesion of Mesenchymal Stem Cells

간엽 줄기 세포의 종양 특이적 부착성을 알아보기 위해 간염 줄기 세포와 정상 인간 섬유 아세포 IMR-90 세포주에 부유 종양 세포주인 SNU-16 세포주를 투여해 보았다. 그 다음날 관찰해 본 결과 부유 종양 세포주가 강하게 부착됨에 비해 정상 섬유 아세포주 IMR-90엔 부착되지 않음을 확인한다 (도 2 참조). 따라서 간엽 줄기 세포엔 종양 특이적 부착 능력이 있음을 확인한다. 따라서 이러한 종양 세포 특이적 부착 능력을 갖는 간엽 줄기 세포를 종양 유전자 치료에 이용한다면 종양 세포만을 선택적으로 사멸 시킬 수 있을 것이다.To investigate the tumor-specific adhesion of mesenchymal stem cells, a floating tumor cell line, SNU-16 cell line, was administered to hepatitis stem cells and normal human fibroblast IMR-90 cell lines. Observation of the next day confirms that the floating tumor cell line is not attached to the normal fibroblast cell line IMR-90 yen, compared with the strong attachment (see FIG. 2). Therefore, it is confirmed that mesenchymal stem cells have tumor-specific adhesion ability. Therefore, if the mesenchymal stem cells having such tumor cell specific adhesion ability are used for tumor gene therapy, only tumor cells may be selectively killed.

실시예 4 아데노바이러스 감염시킨 간엽 줄기 세포에 의한 종양 세포 살상 효과Example 4 Tumor Cell Killing Effect by Adenovirus Infected Mesenchymal Stem Cells

아데노바이러스에 의해 감염된 간엽 줄기세포에서 분비되는 p53 유전자에 의한 세포 살상 효과를 알아보기 위해 아데노바이러스 간염 간엽 줄기 세포의 상층액을 각 종양 세포주에 투여한 후 6일 후 미국 프로메가사 제품인 CytoTox 96Non-Radioactive Cytotoxicity assay kit를 이용해 세포 살상도를 측정해 보았다. 그 결과 Ad5.CMV-hp3 감염 간엽 줄기 세포의 상층액이 세포 살상 효과를 갖음을 알 수 있다 (도 3 참조).To investigate the cell killing effect of p53 gene secreted from mesenchymal stem cells infected with adenovirus, supernatant of adenovirus hepatitis mesenchymal stem cells was administered to each tumor cell line 6 days after CytoTox 96, a US Promega company. Cell killing was measured using a non-radioactive cytotoxicity assay kit. As a result, it can be seen that the supernatant of Ad5.CMV-hp3 infected mesenchymal stem cells has a cytotoxic effect (see FIG. 3).

본 발명의 p53 과량 분비 간엽 줄기세포는 암세포를 추적해 부착해서 과량의 p53 분비함으로써 암세포를 사멸시키거나, 성장을 억제시키는데 탁월한 효과를 나타낼 것으로 기대된다. 또한 상기 세포는 기존의 바이러스 유래 유전자 벡터의 부작용인 면역 반응이나 낮은 전달 효율성, 제조 및 정제과정의 어려움 등의 문제점을 일시에 해결이 가능하고, 항원 항체 반응을 일으키지 않아 암환자에게 직접 투여가 가능한 새로운 차원의 항암 유전자 요법으로 기대가 매우 크다.The p53 excess secretory mesenchymal stem cells of the present invention are expected to exhibit excellent effects in killing or inhibiting growth of cancer cells by tracking and attaching and secreting excess p53. In addition, the cells can solve the problems such as immune response, low delivery efficiency, difficulty in manufacturing and purification, which are side effects of the existing virus-derived gene vector, and can be directly administered to cancer patients without causing antigen antibody response. Expectations are high with new levels of anticancer gene therapy.

Claims (1)

종양 추적 능력이 있으며 p53을 과량 분비하는 인간 간엽 줄기 세포 제조 방법 및 이를 항암 치료에 사용하는 용도Method for producing human mesenchymal stem cells with tumor tracking ability and excessive secretion of p53 and use thereof in anticancer treatment [참고문헌][references]
KR1020020054787A 2002-09-06 2002-09-06 Method for anticancer treatment using human mesenhymal stem cell and adenovirus producing p53 KR20040022134A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020020054787A KR20040022134A (en) 2002-09-06 2002-09-06 Method for anticancer treatment using human mesenhymal stem cell and adenovirus producing p53

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020020054787A KR20040022134A (en) 2002-09-06 2002-09-06 Method for anticancer treatment using human mesenhymal stem cell and adenovirus producing p53

Publications (1)

Publication Number Publication Date
KR20040022134A true KR20040022134A (en) 2004-03-11

Family

ID=37326075

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020020054787A KR20040022134A (en) 2002-09-06 2002-09-06 Method for anticancer treatment using human mesenhymal stem cell and adenovirus producing p53

Country Status (1)

Country Link
KR (1) KR20040022134A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1727892A1 (en) * 2004-03-22 2006-12-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
WO2009028870A3 (en) * 2007-08-29 2009-04-23 Medipost Co Ltd Composition for the diagnosis, prevention or treatment of diseases related to cells expressing il-8 or gro-alpha, comprising ucb-mscs

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1727892A1 (en) * 2004-03-22 2006-12-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
EP1727892A4 (en) * 2004-03-22 2007-08-22 Osiris Therapeutics Inc Mesenchymal stem cells and uses therefor
US9694035B2 (en) 2004-03-22 2017-07-04 Mesoblast International Sarl Mesenchymal stem cells and uses therefor
US9943547B2 (en) 2004-03-22 2018-04-17 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US10668101B2 (en) 2004-03-22 2020-06-02 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US10716814B2 (en) 2004-03-22 2020-07-21 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US10729727B2 (en) 2004-03-22 2020-08-04 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US10828334B1 (en) 2004-03-22 2020-11-10 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US10960025B2 (en) 2004-03-22 2021-03-30 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US11389484B2 (en) 2004-03-22 2022-07-19 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
WO2009028870A3 (en) * 2007-08-29 2009-04-23 Medipost Co Ltd Composition for the diagnosis, prevention or treatment of diseases related to cells expressing il-8 or gro-alpha, comprising ucb-mscs
US8506948B2 (en) 2007-08-29 2013-08-13 Medipost Co., Ltd. UCB-MSCs comprising a tumor suppressor gene reduce the size of an IL-8 or GRO-αexpressing tumor

Similar Documents

Publication Publication Date Title
CN104582711B (en) pluripotent stem cells for inducing repair and regeneration of myocardial infarction
ES2391573T3 (en) Method for the treatment of activation of an antigen presenting cell
ES2616457T3 (en) Treatment of amyotrophic lateral sclerosis using umbilical derived cells
BG106028A (en) Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
KR20150009528A (en) Immortalized stem cells and medicinal composition and medicinal preparation comprising product thereof as active ingredient
JP2012502653A (en) Induced pluripotent stem cell marker
JP2005151907A5 (en)
US20160068805A1 (en) Method to expand and transduce cultured human small and large intestinal stem cells
Mercapide et al. Primary gene‐engineered neural stem/progenitor cells demonstrate tumor‐selective migration and antitumor effects in glioma
JP2005151907A (en) Human stem cell derived from placenta or amnion and method for establishing the same and method for differentiation-induction to organ
CZ227198A3 (en) Genetically changed cells and their use in prophylaxis or treating of diseases
Xiang et al. Direct in vivo application of induced pluripotent stem cells is feasible and can be safe
Miyamoto et al. Neoplastic transformation of mouse mammary epithelial cells by in vitro exposure to N-methyl-N-nitrosourea.
US20090186007A1 (en) Use of cells derived from adipose tissue for the preparation of an anti-tumor medicament
JP2023060125A (en) Treatment agent for epidermolysis bullosa
Zeng et al. ILK regulates MSCs survival and angiogenesis partially through AKT and mTOR signaling pathways
Bryukhovetskiy et al. Cancer stem cells and microglia in the processes of glioblastoma multiforme invasive growth
CA3149478A1 (en) Cellular compositions comprising viral vectors and methods of treatment
Taeb et al. Update on mesenchymal stem cells: a crucial player in cancer immunotherapy
Tsurushima et al. Induction of human autologous cytotoxic T lymphocytes against minced tissues of glioblastoma multiforme
KR100492017B1 (en) Method for anticancer treatment using human mesenhymal stem cell
KR20040022134A (en) Method for anticancer treatment using human mesenhymal stem cell and adenovirus producing p53
KR20030068696A (en) Enhancement of in-vivo stem cell engraftment by increasing stat3 activity
WO2021201286A1 (en) High-potential pluripotent stem cells
KR20100114170A (en) Composition for anticancer containing umbilical cord blood- or adipose tissue-derived stem cell

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application